Dozens of Indian drugmakers have launched cut-price versions of teneligliptin, a new generation medicine for type 2 diabetes patients.

Glenmark Pharmaceuticals is expecting approvals for four to six new products during the fiscal from the US Food and Drug Administration (US...

A new anti-diabetes drug from the 'gliptin' family soon to be launched in India promises to lower treatment cost for patients by 55-60%.